Aclarion (ACON) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting will be held in December 2024 to elect seven directors, ratify the auditor, approve share issuances under financing agreements, authorize a reverse stock split, and amend the equity incentive plan.
The board recommends voting in favor of all proposals, including director elections, auditor ratification, share issuances, reverse stock split, and equity plan amendment.
Only stockholders of record as of November 2024 are entitled to vote; voting can be done in person, by mail, or online.
Voting matters and shareholder proposals
Proposals include electing seven directors, ratifying Haynie & Company as auditor, authorizing share issuances under the ELOC, Series B and C Preferred financings, approving a reverse stock split, and amending the 2022 Equity Incentive Plan.
Shareholder approval is sought for share issuances exceeding 19.99% of outstanding shares under Nasdaq rules.
The reverse stock split proposal allows the board to combine shares at a ratio between 1-for-5 and 1-for-400 within one year.
Stockholders may submit proposals for the 2025 meeting in accordance with SEC and bylaw requirements.
Board of directors and corporate governance
Seven director nominees, all current directors, are up for election; most are independent except for three.
The board has audit, compensation, and nominating/governance committees, each with independent members and defined charters.
The board values diversity and has a formal process for nominating directors, including stockholder recommendations.
A lead independent director provides oversight when the chairman is also an executive officer.
Latest events from Aclarion
- Revenue up 65.6% to $75.7K; net loss $7.2M; $22.6M raised in 2025, $10.4M in 2026.ACON
Q4 202518 Mar 2026 - Non-invasive spinal diagnostics see clinical, commercial, and reimbursement momentum in key markets.ACON
Investor Update23 Jan 2026 - Non-invasive lumbar disc diagnostics show strong outcomes and payer traction, driving expansion.ACON
Investor Update12 Jan 2026 - Shelf registration enables up to $50M in offerings for AI-driven spine diagnostics in a high-need market.ACON
Registration Filing16 Dec 2025 - Healthcare tech firm targets $50M raise amid Nasdaq risks, leveraging patented MRS diagnostics.ACON
Registration Filing16 Dec 2025 - AI-driven diagnostics firm faces Nasdaq risks, offers 27.5M shares for resale, no direct proceeds.ACON
Registration Filing16 Dec 2025 - Up to $150M in securities to fund AI-driven diagnostics for back and neck pain; high risk, high potential.ACON
Registration Filing16 Dec 2025 - Key votes include director elections, auditor ratification, a reverse split, and equity plan changes.ACON
Proxy Filing2 Dec 2025 - Vote sought on a reverse stock split to regain Nasdaq compliance and broaden investor appeal.ACON
Proxy Filing2 Dec 2025